Research programme: human epidermal growth factor receptor 2 (HER2) exon 20 inhibitors - Boehringer Ingelheim
Alternative Names: HER2 exon 20 inhibitor - Boehringer IngelheimLatest Information Update: 31 May 2021
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 10 Apr 2021 Pharmacodynamics data from a preclinical study in Non-small cell lung cancer presented at the (112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 10 Apr 2021 Boehringer Ingelheim plans a clinical trial for Non-small cell lung cancer
- 10 Apr 2021 Preclinical trials in Non-small cell lung cancer in Germany (unspecified route)